| | | | | | | | | | |
|
|
| Dockets Entered
On July 18, 2007
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1998N-0359
|
| Program priorities/Center for Food Safety & Applied Nutrition
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
| 2005N-0272
|
| Irradiation in the Production, Processing & Handling of Food
|
|
|
| 2006D-0480
|
| Guidance for Industry
on Complementary & Alternative Medicine Products & Their Regulation
by the Food and Drug Administration
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
| 2006P-0218
|
| To permit an abbrevation New Drug Application Triamcinolone Diacetate Suspension
|
|
|
| 2007D-0106
|
| Guidance for Clinical Investigators, Sponsors, and IRBs on Adverse Event Reporting Improving Human Subject Protection
|
|
|
| 2007N-0121
|
| Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
|
|
|
| 2007N-0208
|
| Interim Melamine and Melamine Analogues Safety/Risk Assessment; Availability
|
|
|
| 2007P-0023
|
| Modify the in vitro breakpoints for penicillin and Streptococcus pneumoniae originally set by Clinical and Laboratory Standards Institute
|
|
|
| 2007P-0028
|
| Determine whether Seroquel, 150 mg ( quetiapine fumarate ) tablets ( NDA 20-639 ) has been withdrawn for safety or effectiveness reasons
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|
|
| 1998N-0359
|
| Program priorities/Center for Food Safety & Applied Nutrition
|
|
|
| C 126
|
| National Alliance for Breastfeeding Advocacy (NABA)
|
| Vol #:
|
| 10
|
|
|
| 2003N-0573
|
| Draft Animal Cloning Risk Assessment
|
|
|
| C 4059
|
| M. Jonas
|
| Vol #:
|
| 238
|
|
|
| C 4060
|
| D. Roth
|
| Vol #:
|
| 238
|
|
|
| C 4061
|
| I. Armos
|
| Vol #:
|
| 238
|
|
|
| C 4062
|
| O. Smith
|
| Vol #:
|
| 238
|
|
|
| C 4063
|
| A. Morris
|
| Vol #:
|
| 238
|
|
|
| 2005N-0272
|
| Irradiation in the Production, Processing & Handling of Food
|
|
|
| C 1725
|
| J. Novack
|
| Vol #:
|
| 19
|
|
|
| C 1726
|
| S. Grannell
|
| Vol #:
|
| 19
|
|
|
| C 1727
|
| A. Hernandez
|
| Vol #:
|
| 19
|
|
|
| C 1728
|
| C. J. Hayes
|
| Vol #:
|
| 19
|
|
|
| C 1729
|
| C. Moschopulos
|
| Vol #:
|
| 19
|
|
|
| C 1730
|
| T. Wiebe
|
| Vol #:
|
| 19
|
|
|
| C 1731
|
| L. Parham
|
| Vol #:
|
| 19
|
|
|
| C 1732
|
| B. Cornelius
|
| Vol #:
|
| 19
|
|
|
| C 1733
|
| D. O'neill
|
| Vol #:
|
| 19
|
|
|
| C 1734
|
| T. Reed
|
| Vol #:
|
| 19
|
|
|
| C 1735
|
| V. & J. Volmensky
|
| Vol #:
|
| 19
|
|
|
| C 1736
|
| K. Lott
|
| Vol #:
|
| 19
|
|
|
| C 1737
|
| T. W. Sanchez
|
| Vol #:
|
| 19
|
|
| | | | | | | | |
|
|
| C 1350
|
| R. Walker
|
| Vol #:
|
| 25
|
|
|
| C 1351
|
| E. Cleveland
|
| Vol #:
|
| 25
|
|
|
| C 1352
|
| C. Getzyy
|
| Vol #:
|
| 25
|
|
|
| C 1353
|
| K. Hoffman
|
| Vol #:
|
| 25
|
|
|
| C 1354
|
| M. Lindic
|
| Vol #:
|
| 25
|
|
|
| C 1355
|
| N. Lindic
|
| Vol #:
|
| 25
|
|
|
| C 1356
|
| K. Goldberg
|
| Vol #:
|
| 25
|
|
|
| C 1357
|
| I. Edmonds
|
| Vol #:
|
| 25
|
|
|
| C 1358
|
| L. McElyea
|
| Vol #:
|
| 25
|
|
|
| C 1359
|
| G. Weymouth
|
| Vol #:
|
| 25
|
|
|
| C 1360
|
| D. Offemaria
|
| Vol #:
|
| 25
|
|
|
| C 1361
|
| W. Wilson
|
| Vol #:
|
| 25
|
|
|
| C 1362
|
| J. Schattel
|
| Vol #:
|
| 25
|
|
|
| C 1363
|
| M. Frankel
|
| Vol #:
|
| 25
|
|
|
| C 1364
|
| P. Whitehead
|
| Vol #:
|
| 25
|
|
|
| 2006N-0454
|
| Use of Ozone-Depleting Substances; Removal of Essential-Use Designations
|
|
|
| LET 1
|
| University of Alabama at Birmingahm (UAB)
|
| Vol #:
|
| 1
|
|
|
| 2006P-0218
|
| To permit an abbrevation New Drug Application Triamcinolone Diacetate Suspension
|
|
|
| LET 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007D-0106
|
| Guidance for Clinical Investigators, Sponsors, and IRBs on Adverse Event Reporting Improving Human Subject Protection
|
|
|
| C 8
|
| Kendle
|
| Vol #:
|
| 1
|
|
|
| 2007N-0121
|
| Use of Medication Guides to Distribute Drug Risk Information to Patients; Public Hearing
|
|
|
| C 7
|
| Pfizer Inc.
|
| Vol #:
|
| 7
|
|
|
| 2007N-0208
|
| Interim Melamine and Melamine Analogues Safety/Risk Assessment; Availability
|
|
|
| EC 2
|
| Ms. Rose Liss
|
| Vol #:
|
| 1
|
|
|
| EC 3
|
| Mrs. Wendy Smuda
|
| Vol #:
|
| 1
|
|
|
| 2007P-0023
|
| Modify the in vitro breakpoints for penicillin and Streptococcus pneumoniae originally set by Clinical and Laboratory Standards Institute
|
|
|
| LET 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| LET 2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007P-0028
|
| Determine whether Seroquel, 150 mg ( quetiapine fumarate ) tablets ( NDA 20-639 ) has been withdrawn for safety or effectiveness reasons
|
|
|
| LET 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2007P-0085
|
| Adopt Regulations of General Applicability to all Food Standards that would Permit Deviations from the Requirements of the Individual Food Standards of Identity
|
|